One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent ...

Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In this article, we are going to ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Pfizer Inc. (NYSE: PFE), and AstraZeneca plc (NASDAQ: AZN) may have faded from the spotlight since the peak of the COVID-19 ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

It has been about a month since the last earnings report for Pfizer (PFE). Shares have lost about 9.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

The world’s largest pharmaceutical company by 2023 revenue, Pfizer Inc. (PFE) is down more than 13% year-to-date, while the ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...